Meibomian gland dysfunction (MGD) is the leading cause of dry eye disease, which affects tens of millions of Americans. However, there is no FDA-approved treatment for MGD. Researchers from the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School have just identified a potential therapy.
"We discovered that azithromycin, an antibiotic, can directly stimulate the function of human meibomian gland epithelial cells," said First Author Yang Liu, M.D., a postdoctoral fellow at Schepens Eye Research Institute and Harvard Medical School. Their finding is outlined in a Research Letter that was published Online First in JAMA Ophthalmology.
This finding is very clinically significant, because topical azithromycin is the most commonly prescribed MGD treatment in the USA, but its use is 'off-label,' which means the drug's efficacy has not yet been evaluated and approved by the Food and Drug Administration for patients with MGD. This antibiotic has been presumed to be effective because of its anti-inflammatory and anti-bacterial actions, which may suppress the MGD-associated conjunctival inflammation (i.e. posterior blepharitis) and growth of lid bacteria.
"We hypothesized that azithromycin could act directly on human meibomian gland epithelial cells to stimulate their differentiation, enhance the quality and quantity of their lipid production, and promote their holocrine secretion. Our results support this hypothesis," said Senior Author David A. Sullivan, Ph.D., Senior Scientist and Margaret S. Sinon Scholar in Ocular Surface Research, Schepens Eye Research Institute and Associate Professor of Ophthalmology, Harvard Medical School.
The findings in this study may help lead to broader use of topical azithromycin as an FDA-approved, 'on-label' treatment to ameliorate the pathophysiology of MGD and its associated evaporative dry eye disease.
Explore further: Ranibizumab may prevent retinal detachment side effect
More information: Yang Liu, M.D.; Wendy R. Kam, M.S.; Juan Ding, Ph.D.; and David A. Sullivan, Ph.D. JAMA Ophthalmology archopht.jamanetwork.com/article.aspx?articleid=1792853
Medical Xpress on facebook
Related Stories
IOVS publishes consensus findings on meibomian gland dysfunction
Mar 31, 2011
The first global consensus report on meibomian gland dysfunction — a major cause of lid disease and evaporative dry eye — has been published in a special issue of the Investigative Ophthalmology & Visual Science (IOVS) ...
Ranibizumab may prevent retinal detachment side effect
Apr 09, 2013
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, ...
Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month
Dec 09, 2013
For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts ...
Topical use of arthritis drug provides relief for dry eye disease
Apr 18, 2013
Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life. An estimated nine million people ...
Got dry eyes? Measuring eyelid sensitivity may reflect the causes
Oct 03, 2012
A simple test of eyelid sensitivity may help vision professionals in evaluating one of the most common eye-related symptoms: dry eyes. A new study linking increased eyelid sensitivity to decreased function of the eyelid margins ...
Recommended for you
Scientists use drug to repair rare birth defect
Dec 20, 2013
University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.
Angiogenic factor secretion by melanocytes associated with pigmentation leve
Dec 20, 2013
The decreased vision loss that accompanies age-related macular degeneration (AMD) is associated with abnormal blood vessel growth in the eye. Frequencies of AMD development are different among racial backgrounds, with occurrence ...
Many people with diabetes still lose vision, despite availability of vision-sparing treatment
Dec 19, 2013
Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the ...
Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month
Dec 09, 2013
For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts ...
Poor people with diabetes may miss out on eye care
Dec 06, 2013
(HealthDay)—People with diabetes are at increased risk for eye problems, but a new study finds that poor diabetes patients who go to public hospital clinics have low rates of eye care.
How our vision dims: Chemists crack the code of cataract creation
Dec 05, 2013
Groundbreaking new findings by UC Irvine and German chemists about how cataracts form could be used to help prevent the world's leading cause of blindness, which currently affects nearly 20 million people ...
User comments
© Medical Xpress 2011-2013, Science X network
Meibomian gland dysfunction (MGD) is the leading cause of dry eye disease, which affects tens of millions of Americans. However, there is no FDA-approved treatment for MGD. Researchers from the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School have just identified a potential therapy.
"We discovered that azithromycin, an antibiotic, can directly stimulate the function of human meibomian gland epithelial cells," said First Author Yang Liu, M.D., a postdoctoral fellow at Schepens Eye Research Institute and Harvard Medical School. Their finding is outlined in a Research Letter that was published Online First in JAMA Ophthalmology.
This finding is very clinically significant, because topical azithromycin is the most commonly prescribed MGD treatment in the USA, but its use is 'off-label,' which means the drug's efficacy has not yet been evaluated and approved by the Food and Drug Administration for patients with MGD. This antibiotic has been presumed to be effective because of its anti-inflammatory and anti-bacterial actions, which may suppress the MGD-associated conjunctival inflammation (i.e. posterior blepharitis) and growth of lid bacteria.
"We hypothesized that azithromycin could act directly on human meibomian gland epithelial cells to stimulate their differentiation, enhance the quality and quantity of their lipid production, and promote their holocrine secretion. Our results support this hypothesis," said Senior Author David A. Sullivan, Ph.D., Senior Scientist and Margaret S. Sinon Scholar in Ocular Surface Research, Schepens Eye Research Institute and Associate Professor of Ophthalmology, Harvard Medical School.
The findings in this study may help lead to broader use of topical azithromycin as an FDA-approved, 'on-label' treatment to ameliorate the pathophysiology of MGD and its associated evaporative dry eye disease.
Explore further: Ranibizumab may prevent retinal detachment side effect
More information: Yang Liu, M.D.; Wendy R. Kam, M.S.; Juan Ding, Ph.D.; and David A. Sullivan, Ph.D. JAMA Ophthalmology archopht.jamanetwork.com/article.aspx?articleid=1792853
Medical Xpress on facebook
Related Stories
IOVS publishes consensus findings on meibomian gland dysfunction
Mar 31, 2011
The first global consensus report on meibomian gland dysfunction — a major cause of lid disease and evaporative dry eye — has been published in a special issue of the Investigative Ophthalmology & Visual Science (IOVS) ...
Ranibizumab may prevent retinal detachment side effect
Apr 09, 2013
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, ...
Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month
Dec 09, 2013
For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts ...
Topical use of arthritis drug provides relief for dry eye disease
Apr 18, 2013
Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life. An estimated nine million people ...
Got dry eyes? Measuring eyelid sensitivity may reflect the causes
Oct 03, 2012
A simple test of eyelid sensitivity may help vision professionals in evaluating one of the most common eye-related symptoms: dry eyes. A new study linking increased eyelid sensitivity to decreased function of the eyelid margins ...
Recommended for you
Scientists use drug to repair rare birth defect
Dec 20, 2013
University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.
Angiogenic factor secretion by melanocytes associated with pigmentation leve
Dec 20, 2013
The decreased vision loss that accompanies age-related macular degeneration (AMD) is associated with abnormal blood vessel growth in the eye. Frequencies of AMD development are different among racial backgrounds, with occurrence ...
Many people with diabetes still lose vision, despite availability of vision-sparing treatment
Dec 19, 2013
Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the ...
Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month
Dec 09, 2013
For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts ...
Poor people with diabetes may miss out on eye care
Dec 06, 2013
(HealthDay)—People with diabetes are at increased risk for eye problems, but a new study finds that poor diabetes patients who go to public hospital clinics have low rates of eye care.
How our vision dims: Chemists crack the code of cataract creation
Dec 05, 2013
Groundbreaking new findings by UC Irvine and German chemists about how cataracts form could be used to help prevent the world's leading cause of blindness, which currently affects nearly 20 million people ...
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment